Evaluation of the Effects Associated With the Administration of Akkermansia Muciniphila on Parameters of Metabolic Syndrome

Exclusion Criteria

• •Acute or chronic progressive or chronic unstabilized diseases
• •Alcohol consumption (more than 2 glasses per day)
• •Previous bariatric surgery
• •Surgery in the 3 months prior the study or surgery planned in the next 6 months
• •Pregnancy or pregnancy planned in the next 6 months
• •More than 30 minutes of sports 3 times per week
• •Consumption of dietary supplement (omega-3 fatty acids, probiotics, prebiotics, plant stanols/sterols) in the month prior the study
• •Inflammatory bowel disease or irritable bowel syndrome
• •Diabetic gastrointestinal autonomic neuropathy (such as gastroparesis or reduced gastrointestinal motility)
• •Consumption of more than 30g of dietary fibers per day
• •Vegetarian or unusual diet
• •Lactose intolerance or milk protein allergy
• •Gluten intolerance
• •Medications influencing parameters of interest (antidiabetic drugs such as metformin, DPP-4 inhibitors, GLP-1 receptor agonists, acarbose, hypoglycemic sulfonamides,glinides, thiazolidinediones, SGLT2 inhibitors, insulin,lactulose, consumption of antibiotics in the 2 months prior the study, corticosteroids, immunosuppressive agents, statins, fibrate, orlistat, cholestyramine, ezetimibe)
• •Glycated hemoglobin (HbA1c) \> 7.5%